403 related articles for article (PubMed ID: 27480090)
21. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
22. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
[TBL] [Abstract][Full Text] [Related]
23. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT.
Giebel S; Labopin M; Czerw T; Socié G; Blaise D; Ghavamzadeh A; Passweg J; Ljungman P; Poiré X; Chevallier P; Reményi P; Rambaldi A; Anafasyev B; Fegueux N; Rovira M; Itälä-Remes M; Bornhäuser M; Mohty M; Nagler A
Eur J Cancer; 2019 Jan; 106():212-219. PubMed ID: 30528805
[TBL] [Abstract][Full Text] [Related]
24. Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis.
Salas MQ; Lam W; Law AD; Kim DDH; Michelis FV; Loach D; Al-Shaibani Z; Lipton JH; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2019 Dec; 103(6):597-606. PubMed ID: 31514253
[TBL] [Abstract][Full Text] [Related]
25. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Rischewski J; Sonnenberg S; Ayuk F; Tögel F; Schade U; Fiegel H; Erttmann R; Löliger C; Zander AR
Bone Marrow Transplant; 2002 Apr; 29(8):683-9. PubMed ID: 12180114
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
27. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation.
Storek J; Mohty M; Boelens JJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):959-70. PubMed ID: 25482864
[TBL] [Abstract][Full Text] [Related]
28. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
30. Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.
Hannon M; Beguin Y; Ehx G; Servais S; Seidel L; Graux C; Maertens J; Kerre T; Daulne C; de Bock M; Fillet M; Ory A; Willems E; Gothot A; Humblet-Baron S; Baron F
Clin Cancer Res; 2015 Jul; 21(14):3131-9. PubMed ID: 25779951
[TBL] [Abstract][Full Text] [Related]
31. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.
Nishihori T; Al-Kadhimi Z; Hamadani M; Kharfan-Dabaja MA
Immunotherapy; 2016; 8(4):435-47. PubMed ID: 26973125
[TBL] [Abstract][Full Text] [Related]
32. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies.
Goussetis E; Efstathiou E; Paisiou A; Avgerinou G; Zisaki K; Giamouris VJ; Peristeri I; Kitra V; Vessalas G; Gamaletsou MN; Sipsas NV; Graphakos S
Transpl Infect Dis; 2015 Apr; 17(2):201-7. PubMed ID: 25645592
[TBL] [Abstract][Full Text] [Related]
33. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
34. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.
Waller EK; Langston AA; Lonial S; Cherry J; Somani J; Allen AJ; Rosenthal H; Redei I
Biol Blood Marrow Transplant; 2003 Jul; 9(7):460-71. PubMed ID: 12869960
[TBL] [Abstract][Full Text] [Related]
36. Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.
Li Q; Meng F; Zhou M; Yu B; Mo W; Du Q; Jiang X; Wei Y
Med Sci Monit; 2015 Aug; 21():2257-65. PubMed ID: 26238068
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
38. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
39. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
40. Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?
Shichijo T; Fuji S; Nagler A; Bazarbachi A; Mohty M; Savani BN
Bone Marrow Transplant; 2020 Mar; 55(3):505-522. PubMed ID: 31435032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
